Is A Merger Out Of Reach After This Biotech Inked A $2 Billion Licensing Deal?Investors Business Daily • 06/24/20
uniQure Announces License Agreement with CSL Behring to Commercialize Hemophilia B Gene TherapyGlobeNewsWire • 06/24/20
uniQure Announces First Two Patients Treated in Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington’s DiseaseGlobeNewsWire • 06/19/20
uniQure Announces Achievement of Target Patient Dosing in HOPE-B Pivotal Trial of AMT-061 (Etranacogene Dezaparvovec) in Hemophilia BGlobeNewsWire • 03/26/20
uniQure and Gen-X Enter into Research Collaboration and License Agreement for the Development of Novel Synthetic PromotersGlobeNewsWire • 03/02/20
UniQure (QURE) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research • 02/20/20
uniQure Announces Publication of Preclinical Data for AMT-130 in Huntington’s Disease Supporting Non-Selective HTT-Lowering ApproachGlobeNewsWire • 12/19/19
uniQure Announces One-Year Follow-Up Data from the Phase IIb Study of Etranacogene Dezaparvovec and Long-Term Follow-Up Data for AMT-060 in Patients with Hemophilia BGlobeNewsWire • 12/08/19